Compare SDST & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDST | TXMD |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 24.4M |
| IPO Year | N/A | 2012 |
| Metric | SDST | TXMD |
|---|---|---|
| Price | $1.78 | $1.92 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 140.7K | 34.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $188.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.14 | $0.98 |
| 52 Week High | $7.67 | $2.95 |
| Indicator | SDST | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.02 | 30.48 |
| Support Level | $0.28 | $1.60 |
| Resistance Level | $2.85 | $2.09 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 3.08 | 13.78 |
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.